TriAltus Bioscience

TriAltus Bioscience Protein Purification Technology Supports Providence Cancer Institute COVID-19 Vaccine Development

“It’s rewarding to know that our product can help expedite the search for a COVID-19 vaccine,” said TriAltus Bioscience CEO Bob Shufflebarger. “Our CL7/Im7 system is helping Dr. Hu and his colleagues attain high protein purity in a single-step process that saves critical time and boosts research productivity.”
Exit mobile version